This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Pediatric Long-Term Follow-up and Rollover Study | MicrobiomeTrials
← Back to trials NCT03975829
Pediatric Long-Term Follow-up and Rollover Study Recruiting PHASE4 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2019-11-04Est. Completion: 2026-11-05
Enrollment target: 163 participantsLocations Phoenix Children s Hospital, Phoenix, Arizona, United States Childrens National Hospital, Washington D.C., District of Columbia, United States Nicklaus Childrens Hospital, Miami, Florida, United States Indiana Uni School of Medicine, Indianapolis, Indiana, United States Johns Hopkins Hospital, Baltimore, Maryland, United States Dana Farber Cancer Institute, Boston, Massachusetts, United States University of Minnesota, Minneapolis, Minnesota, United States Memorial Sloan Kettering Cancer Center, New York, New York, United States Memorial Sloan Kettering Cancer Ctr, New York, New York, United States Cinn Children Hosp Medical Center, Cincinnati, Ohio, United States St Jude Childrens Research Hospital, Memphis, Tennessee, United States Texas Childrens Hospital, Houston, Texas, United States Novartis Investigative Site, CABA, Buenos Aires, Argentina Novartis Investigative Site, Darlinghurst, New South Wales, Australia Novartis Investigative Site, Parkville, Victoria, Australia Novartis Investigative Site, Brussels, Belgium Other microbiome trials you might be interested in Glioma Recurrence Disease Attributes Pathologic Processes Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Diffuse Glioma Diffuse Glioma With IDH1 or IDH2 Mutations
This is an expanded access program to provide vorasidenib for treatment of patients 12 years or older with IDH1- or IDH2…
Multiple Locations
Novartis Investigative Site, Barretos, São Paulo, Brazil
Novartis Investigative Site, São Paulo, São Paulo, Brazil
Novartis Investigative Site, São Paulo, São Paulo, Brazil
Novartis Investigative Site, Vancouver, British Columbia, Canada
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Brno, Czechia
Novartis Investigative Site, Prague, Czechia
Novartis Investigative Site, Copenhagen, Denmark
Novartis Investigative Site, Tampere, Finland
Novartis Investigative Site, Rennes, Brittany Region, France
Novartis Investigative Site, Brest, France
Novartis Investigative Site, Marseille, France
Novartis Investigative Site, Paris, France
Novartis Investigative Site, Rennes, France
Novartis Investigative Site, Vandœuvre-lès-Nancy, France
Novartis Investigative Site, Villejuif, France
Novartis Investigative Site, Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site, Augsburg, Germany
Novartis Investigative Site, Berlin, Germany
Novartis Investigative Site, Essen, Germany
Novartis Investigative Site, Hamburg, Germany
Novartis Investigative Site, Petah Tikva, Israel
Novartis Investigative Site, Florence, FI, Italy
Novartis Investigative Site, Genova, GE, Italy
Novartis Investigative Site, Milan, MI, Italy
Novartis Investigative Site, Roma, RM, Italy
Novartis Investigative Site, Torino, TO, Italy
Novartis Investigative Site, Setagaya-ku, Tokyo, Japan
Novartis Investigative Site, Osaka, Japan
Novartis Investigative Site, Utrecht, Netherlands
Novartis Investigative Site, Moscow, Russia
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Valencia, Spain
Novartis Investigative Site, Stockholm, Sweden
Novartis Investigative Site, Sutton, Surrey, United Kingdom
Novartis Investigative Site, Liverpool, United Kingdom
Novartis Investigative Site, London, United Kingdom
Novartis Investigative Site, London, United Kingdom Phase 1
Recruiting
Astrocytoma, IDH-Mutant, Grade 2 Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant Recurrent Astrocytoma, IDH-Mutant Recurrent Astrocytoma, IDH-Mutant, Grade 3 Recurrent Astrocytoma, IDH-Mutant, Grade 4 Recurrent Glioblastoma, IDH-Wildtype
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in tr…
Duarte, United States Est. completion Jun 30, 2027
Glioblastoma GBM
The purpose of this research is to test an investigational device using ultrasound along with an investigational drug to…
Boston, United States Est. completion Dec 2027